All just boxes being ticked prior to Merck acquiring the company in my opinion.
I think the catalyst will be a portion of the initial extra 74 patients in 1st line NSCLC having good results helping to prove the synergistic effect of keytruda and efti and Merck will table an offer.
Ann: Immutep expands Part B of TACTI-002 collaboration trial, page-10
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 33.5¢ | $724.1K | 2.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60483 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 55452 | 4 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |